Skip to main content
TipRanks
Go Ultimate75% OFF

Intellia Therapeutics (38I) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Intellia Therapeutics has a market cap or net worth of CHF 1.12B. The enterprise value is CHF 1.45B.

Market Cap
CHF 1.12B
Enterprise Value
CHF 1.45B

Share Statistics

Intellia Therapeutics has 140,358,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
140,358,500
Owned by Insiders
1.83%
Owned by Institutions
95.98%

Financial Efficiency

Intellia Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -57.67%.

Return on Equity (ROE)
-0.61
Return on Assets (ROA)
-0.49
Return on Invested Capital (ROIC)
-57.67%
Return on Capital Employed (ROCE)
-0.60
Revenue Per Employee
179.50K
Profits Per Employee
-1.09M
Employee Count
377
Asset Turnover
0.08
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Intellia Therapeutics is -2.99. Intellia Therapeutics’s PEG ratio is -0.12.

PE Ratio
-2.99
PS Ratio
26.54
PB Ratio
2.29
Price to FCF
-3.92
Price to Operating Cash Flow
-3.95
PEG Ratio
-0.12

Income Statement

In the last 12 months, Intellia Therapeutics had revenue of 67.67M and earned -412.69M in profits. Earnings per share was -3.81.

Revenue
67.67M
Gross Profit
51.75M
Operating Income
-440.99M
Pretax Income
-412.69M
Net Income
-412.69M
EBITDA
-396.77M
Earnings Per Share (EPS)
-3.81

Cash Flow

In the last 12 months, operating cash flow was -355.17M and capital expenditures -2.90M, giving a free cash flow of -358.08M billion.

Operating Cash Flow
-355.17M
Free Cash Flow
-358.08M
Free Cash Flow per Share
-2.55

Dividends & Yields

Intellia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-25.38%
Earnings Yield
-30.25%

Stock Price Statistics

Beta
0.87
52-Week Price Change
-12.61%
50-Day Moving Average
9.95
200-Day Moving Average
9.85
Relative Strength Index (RSI)
12.70
Average Volume (3m)
303

Important Dates

Intellia Therapeutics upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 25, 2027
Ex-Dividend Date
―

Financial Position

Intellia Therapeutics as a current ratio of 5.08, with Debt / Equity ratio of 13.90%

Current Ratio
5.08
Quick Ratio
5.08
Debt to Market Cap
0.07
Net Debt to EBITDA
0.16
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Intellia Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Intellia Therapeutics EV to EBITDA ratio is -3.53, with an EV/FCF ratio of -4.15.

EV to Sales
28.07
EV to EBITDA
-3.53
EV to Free Cash Flow
-4.15
EV to Operating Cash Flow
-4.18

Balance Sheet

Intellia Therapeutics has CHF 474.11M in cash and marketable securities with CHF 230.14M in debt, giving a net cash position of CHF 243.97M billion.

Cash & Marketable Securities
CHF 474.11M
Total Debt
CHF 230.14M
Net Cash
CHF 243.97M
Net Cash Per Share
CHF 1.74
Tangible Book Value Per Share
CHF 4.37

Margins

Gross margin is 84.46%, with operating margin of -821.24%, and net profit margin of -805.75%.

Gross Margin
84.46%
Operating Margin
-821.24%
Pretax Margin
-805.75%
Net Profit Margin
-805.75%
EBITDA Margin
-795.78%
EBIT Margin
-804.59%

Analyst Forecast

The average price target for Intellia Therapeutics is CHF 16.11, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target
CHF 16.11
Price Target Upside
67.76% Upside
Analyst Consensus
Neutral
Analyst Count
11
Revenue Growth Forecast
-14.25%
EPS Growth Forecast
26.86%

Scores

Smart Score
4
AI Score
―